PSNL news & sentiment — Personalis, Inc.

MAY 20·Investing.comHigh

Personalis gains expanded Medicare coverage for breast cancer test

Personalis Inc. has announced expanded Medicare coverage for its NeXT Personal minimal residual disease test. The coverage now includes monitoring treatment response for Stage II-III Triple-Negative Breast Cancer or HER2-positive breast cancer patients receiving neoadjuvant therapy, extending beyond its previous post-surgical recurrence surveillance. This expansion, the company's fourth Medicare milestone for the test, is supported by clinical evidence from the PREDICT-DNA study.

FEB 10·Stocktwits

Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test

Personalis, Inc. (PSNL) stock is rising due to Medicare's decision to reimburse its NeXT Personal molecular residual disease (MRD) test for patients with early- to mid-stage non-small cell lung cancer (NSCLC). This expands coverage beyond breast cancer and provides broader access to the test, which identifies tiny amounts of circulating tumor DNA to detect cancer recurrence earlier. The announcement led to a significant jump in Personalis' stock price and retail investor sentiment.

NOV 4·Zacks Commentary

Personalis ( PSNL ) Reports Q3 Loss, Tops Revenue Estimates

Personalis (PSNL) delivered earnings and revenue surprises of +14.29% and +5.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

$PSNL

Personalis gains expanded Medicare coverage for breast cancer test

Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test

Personalis ( PSNL ) Reports Q3 Loss, Tops Revenue Estimates

News on $PSNL